1. Introduction
Head and neck cancer (HNC) is a global epidemiological and clinical problem. In 2020, it was the seventh most common type of cancer worldwide [
1]. The incidence of HNC is noticeably higher in regions with a low level of economic development, where HNC is the most common type of cancer [
2]. In Central and Eastern European countries, there are also significant adverse epidemiological trends in HNC [
3]. In 2019, HNC was the fourth most common cause of cancer death among men in Poland [
4].
HNCs include malignancies located within the lips, tongue, oral cavity, nasal sinuses, pharynx, salivary glands, and larynx. Despite the diverse location, head and neck cancers are a relatively homogeneous group in terms of histopathological classification. In over 90% of cases, HNCs are squamous cell carcinomas. Typical risk factors for the development of squamous cell carcinomas of the head and neck (HNSCC) include tobacco smoking and excessive alcohol consumption. In recent years, the relationship of HPV infection, in particular the HPV-16 serotype, with an increased risk of HNC has been proven. HPV-related HNCs are clinically and epidemiologically distinct from cancers associated with classical risk factors. HPV-related cancers tend to occur at a younger age in patients with no history of tobacco or alcohol exposure. They are also characterised by a milder course and less frequent distant metastases [
5].
The management of patients with HNC is multidisciplinary in nature. Radiotherapy is a viable treatment option for patients with HNC at all clinical stages, both alone (cT1-2 cN0 cM0) and in combination with surgery and chemotherapy [
6]. Despite the continued advances in personalisation of therapy and good treatment outcomes, radiotherapy treatment is still associated with a significant rate of early and late adverse effects [
7,
8].
As head and neck cancers are located close to vital anatomical structures, both the local progression of the disease and the treatments used can cause serious problems for patients. HNCs and their treatment have, especially in advanced cases, an extremely negative impact on the quality of life [
9]. The impact of the disease on functioning, as well as aesthetic issues, contributes to difficulties in adapting the patient to the state after radical treatment. Patients may experience severe acute and late radiation reactions causing dysfunction of the head and neck organs. Their typical example is drying of the mucous membranes (xerostomia), which is the result of damage to the secretory function of the salivary glands. Impaired salivation causes discomfort and also makes it difficult to eat, leading to malnutrition [
10]. It can also cause dental problems and the need for specialist treatment [
11]. Patients with HNC may also experience dysphagia related to the complex damage to the structure and function of the aerodigestive tract [
12,
13].
Difficulties eating, speaking, and breathing; hearing problems; and changes in the perception of one’s body image affect all areas of personal and professional life [
14,
15,
16]. Therefore, a thorough multifactor analysis of the patient’s quality of life and their ability to independently function should be carried out before, during, and after treatment for HNC [
17].
The aim of this study was to assess the early impact of radiotherapy on health-related quality of life (HRQoL) outcomes, psychological distress, nutritional status, and overall performance of patients with HNC.
2. Materials and Methods
2.1. Study Population
The study was carried out among 85 patients treated in the Inpatient Radiotherapy Unit of the Radiotherapy Department of the Lower Silesian Oncology Center in Wrocław. The criteria for inclusion in the study were as follows: age 18 years or over, diagnosis of primary HNC, radical treatment with radiotherapy, chemoradiotherapy or adjuvant radiotherapy after surgical resection, and provision of voluntary consent to participate in the study. The study was approved by the Bioethics Committee of the Wrocław Medical University (approval no. KB—632/2018).
The study was carried out between July 2018 and February 2019. All participants provided informed written consent to participate in the study. The participants were asked to complete a set of questionnaires twice: before the initiation of radiotherapy treatment and after a course of radiotherapy. The period between the assessments was between 7 and 8 weeks.
2.2. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Head and Neck Cancer 35 (EORTC QLQ-H&N35)
The quality of life of the patients studied was assessed using the Polish language version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Head and Neck Cancer 35 (EORTC QLQ-H&N35). The questionnaire is used to assess the overall quality of life of patients with HNC as well as the symptoms specific to HNC and those related to its treatment [
18,
19].
The EORTC QLQ-H&N35 includes 35 questions, 30 of which assess head and neck pain, problems with swallowing, senses problems, the presence of coughing and hoarseness, problems with feeling ill, trouble with social eating, trouble with social contact, and sexuality during the past week. Patients respond to those questions on a 4-point scale. The remaining 5 questions concern the use of painkillers and nutritional supplements, the use of a feeding tube, weight loss, and weight gain. Those questions request a yes or no answer.
Patient responses are summed for physical, functional, emotional, and social features. They enable the assessment of the impact of cancer and its treatment on particular areas of the patient’s functioning.
The higher the total score, the greater the severity of problems relating to the illness and its treatment and, thus, the poorer the quality of life. A difference (∆) in score of 10 points or more on a scale from 0 to 100 between the two assessment time points (before and after radiotherapy treatment) was considered to be clinically significant, indicating deterioration or improvement in quality of life. This cut-off value is commonly used in studies. A difference (∆) of 20 points or more is considered to be particularly significant [
20].
2.3. Beck Depression Inventory (BDI)
The severity of depressive symptoms was assessed using the Beck Depression Inventory (BDI). The BDI comprises 21 groups of statements concerning mental status and somatic depressive symptoms. Patients are asked to choose one statement in each group the best describes the way they have been feeling during the past week. Each answer is scored on a scale of 0–3. The higher the score, the higher the severity of depressive symptoms. The final score is a sum of all item scores and ranges between 0 and 63 points. Scores below 12 indicate no depression, 12–19 indicate mild depression, 20–25 indicate moderate depression, and 26–63 indicate severe depression [
21]. The BDI is commonly used as a screening tool for a depressive disorder in cancer patients, the accuracy of which has also been confirmed among patients with HNC [
22,
23].
2.4. Nutrition Risk Screening 2002 (NRS-2002) and Body Mass Index (BMI)
The risk of malnutrition was assessed using the Nutrition Risk Screening 2002 (NRS-2002). The NRS-2002 is a tool routinely used to assess nutritional status. It is recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN). The NRS-2002 assesses nutritional status (weight loss and coverage of energy needs) and the potential increase in energy needs resulting from an increase in disease severity. Each of the two components is assigned a score of 0–3. For patients aged over 70 years, an additional 1 point is added to the total score. A score ≥3 indicates the need for nutritional support [
24].
In order to assess the nutritional status of the patients studied, anthropometric measurements, including height and weight, were also taken. They were then used to calculate BMI, i.e., the ratio of body weight in kilograms to height in metres squared. The assessment was carried out twice (before and after radiotherapy treatment).
2.5. ECOG Performance Status Scale
The overall performance status of the patients studied was assessed using the Eastern Cooperative Oncology Group (ECOG) scale. The scale is used to assess the overall condition of cancer patients. It ranges from grade 0 (fully active) to 5 (dead) [
25].
Our own questionnaire used in the study included questions concerning sociodemographic data, such as age, sex, education, and place of residence.
2.6. Statistical Analysis
Our statistical analysis involved calculating scores on particular dimensions of the standardised scales used in the study. Descriptive statistics, i.e., means, minimum and maximum values, medians and standard deviations, were calculated. The t-test or Wilcoxon test was used to compare scores (quantitative variables) of the pre- and post-treatment assessments. The significance level was set at p < 0.05. The analyses were performed using Statistica 13.0 (TIBCO, Palo Alto, Santa Clara, CA, USA).
4. Discussion
The issue of the negative impact of HNC and its treatment on the quality of life, depressive symptoms, and nutritional status of patients is complex and important from the point of view of both public health and clinical practice. The changing epidemiological trends in HNC, and in particular the rising incidence of HPV-related HNC, are reflected in the increase in the number of HNC cases among people aged between 40 and 59 years, and notably in men [
26,
27,
28]. However, the public awareness of HNC, both in the USA and in central and eastern European countries, such as Poland, is relatively low [
29,
30]. Studies have shown that the productivity loss associated with HNC is higher than that associated with other types of cancer [
31,
32]. Moreover, the treatment of HNC can produce a higher financial burden, both to healthcare systems and to patients, compared with other cancers [
33,
34]. This underscores the need for careful analysis of all variables associated with the quality of life and functioning of patients with HNC.
Pretreatment quality of life is a significant prognostic factor for survival in patients with HNC [
35]. In addition, HRQoL is, alongside mortality, survival, and recurrence rates, an important measure of treatment outcomes [
36]. Despite this, there is currently a very limited number of publications in this field concerning the Polish population in the literature.
Our study showed a significant decrease in the immediate QoL outcomes of patients with HNC treated with radiotherapy. Our findings demonstrated a negative impact of acute radiotherapy toxicity on scores in all the cancer-specific functioning scales used in the study. The largest differences were found for the functioning scales relating to senses and swallowing. In addition, a significant deterioration in scores was found for particular cancer-related symptom scales. The largest differences were found for the “sticky saliva” and “dry mouth” scales.
Milecki et al. assessed the changes in the HRQoL in patients with HNC treated with radiotherapy at 12 months after completion of treatment. In terms of the QLQ-H&N35 questionnaire, the authors reported a statistically significant deterioration in the QoL for scales of “dry mouth”, “weight loss”, “senses” “sticky saliva”, “opening mouth”, and “painkillers”. The effect of tumour location on QoL deterioration was statistically significant on the scales “speech” (higher deterioration in patients whose tumour was located in the larynx and hypopharynx) and “opening mouth” (higher deterioration when tumour was located in the oral cavity) [
37].
A comparison of the results of our own research with the those of Milecki et al. points to a greater severity of swallowing difficulties and troubles with social eating among patients immediately after the completion of treatment with radiotherapy.
Problems with chewing and swallowing necessitate a switch to a more liquid diet as well as the use of nutritional supplements, which, in some cases, may necessitate the use of a feeding tube. The eating difficulties experienced by patients with HNC are associated not only with a compromised nutritional status, but also with the feelings of shame when eating in front of others [
38]. In the present study, only two patients reported that they often or very often had problems with social eating prior to the treatment, whereas such problems were reported by more than one-third of patients after radiotherapy treatment.
Dry mouth and sticky saliva are among the most common complaints of patients with HNC treated with radiotherapy, which was also confirmed by the present study. Radiotherapy of the head and neck may cause damage to salivary glands and result in a reduction in saliva production, which has an impact not only on the comfort of patients but also on their chewing ability and taste sensation [
38]. Dysgeusia and ageusia cause patients to quickly lose interest in food, which results in compromised nutritional status and contributes to weight loss [
39].
Over half of the patients included in the present study required nutritional support after radiotherapy treatment. Post-treatment weight loss was reported in 79 of the 85 patients studied. The nutritional status of patients with HNC has a significant impact on their prognosis [
40]. Malnutrition and progressive cachexia are common problems in cancer patients [
41]. Patients with HNC are at particular risk of malnutrition due to the location of the cancer and local-treatment-related toxicity [
42]. Nutritional care should be an integral part of the management of patients with HNC, both during and after treatment [
43]. Intensive nutritional care makes it possible to effectively prevent deterioration in the quality of life of patients with HNC resulting from radiotherapy treatment [
44,
45,
46,
47].
Participants in this study were assessed for the presence of depressive symptoms using the BDI questionnaire. To the best of our knowledge, this is the first study assessing the severity of depressive symptoms among patients with HNC in the Polish population. A mild-to-moderate depressive episode was identified in 45,9% of patients.
The severity of depressive symptoms may also have an impact on the nutritional status of patients with HNC. However, in HNC, depressive symptoms and nutritional status influence each other in a dynamic, rather than static, interplay over time [
48]. The results of the present study showed a statistically significant increase in the severity of depressive symptoms in the patients studied, as measured immediately after radiotherapy treatment. Longitudinal studies of depressive symptoms in patients with HNC undergoing radiotherapy showed that the severity of depressive symptoms in those patients is highest during the treatment [
49]. The results of the present study showed a mild or moderate level of depressive symptom severity, as assessed using the BDI immediately after radiotherapy treatment, in 52.7% of men and 33.3% of women included in the study. The association between sex and the severity of depressive symptoms was not statistically significant. Other studies confirmed a significant prevalence of depressive disorders among patients with HNC [
22].
The side effects of radiotherapy and the resulting reduction in quality of life and increase in the severity of depressive symptoms may cause the patient to no longer want to continue treatment, which may lead to disease progression or recurrence [
50]. Numerous studies have demonstrated a negative impact of interruptions in radiotherapy for HNC on the local control of cancer, survival, and length of survival without recurrence [
51,
52,
53].
The awareness of the negative consequences of radiotherapy treatment and their impact on the patient’s quality of life allows appropriate preventive measures to be taken more quickly, thus increasing the patient’s motivation to complete treatment and their chances of making a full recovery. Complete elimination of the side effects of radiation therapy may not be possible for most patients. In recent years, significant progress has been made in alleviating the symptoms specific to HNC treated with radiotherapy. Despite this, the consequences of radiotherapy, such as xerostomia and salivary hypofunction, are still a significant problem. Reducing radiation damage to the salivary glands, for example, by using intensity-modulated radiation therapy (IMRT), is the primary way to reduce the occurrence of dry mouth [
54]. The use of stem cells to restore salivary gland function remains a promising direction [
55]. Both early and late speech-language pathologist interventions appear to be beneficial in reducing the severity of dysphagia among patients with HNC treated with radiotherapy [
56]. Regarding the nutritional status of patients with HNC, dietary counselling may play a role in counteracting the negative impact of treatment [
57]. A study by Samuel et al. showed a beneficial effect of rehabilitation with exercise on the functioning and quality of life of patients with HNC treated with radiochemotherapy [
58].
The study has several limitations. One is the lack of data definition and analysis based on data on tumour type, stage, location, etc. Future studies should include these data in their analyses. Another limitation of the study is the time of assessment immediately after the end of radiotherapy, which allows for the assessment of the impact of very early toxicity of treatment on QoL, but does not allow for examining the peak of side effects related to progressive fibrosis and scarring. In addition, it would be worth designing a study with a control group in the future. The limitations of this study result from the relatively small study group and the high clinical heterogeneity of patients (e.g., treatment with radiotherapy alone, chemoradiotherapy, or radiotherapy as an adjunct to surgery). Additional studies taking into account the impact of sociodemographic factors and clinical characteristics are required to further specify the risk factors limiting the QoL of patients with HNC.